FIG 4.
LSEVh-LS-F mobilizes ADCC-mediated in vivo elimination of HIV-1-infected cells. (A) Five days after hu-spl-PBMC-NSG mice were inoculated with HIV-1JRCSF-LucR, they were either left untreated or treated with 0.5 mg of LSEVh-LS-F, VRC01, or control antibody m336, and HIV-1 infection was determined by quantifying LucR activity in the splenic lysates the next day. The percent reduction for each mouse compared to the untreated group is presented as a dot plot graph with the group mean ± SD of pooled data from 2 independent experiments using 2 different donors. (B) Seven days after hu-spl-PBMC-NSG mice were inoculated with HIV-1JRCSF-LucR, they were either left untreated or treated with LSEVh-LS-F (0.5 mg). HIV-1 infection indicated by LucR activity was visualized by IVIS live imaging of bioluminescence after injection of the mice with the substrate.